Roy A, Ramalinga M, Kim OJ, Chijioke J, Lynch S, Byers S, et al. Multiple roles of RARRES1 in prostate cancer: Autophagy induction and angiogenesis inhibition. PloS one. 2017;12(7):e0180344.
Taeb J, Asgari M, Abolhasani M, Farajollahi MM, Madjd Z. Expression of prostate stem cell antigen (PSCA) in prostate cancer: a tissue microarray study of Iranian patients. Pathology-Research and Practice. 2014;210(1):18-23.
Abedi A-r, Fallah-Karkan M, Allameh F, Ranjbar A, Shadmehr A. Incidental prostate cancer: a 10-year review of a tertiary center, Tehran, Iran. Research and reports in urology. 2018;10:1.
Javanmard B, Yousefi M, Yaghoobi M, Hadad AH, Amani M, Fadavi B, et al. Ureteral Reimplantation or Percutaneous Nephrostomy: Which One Is Better in Management of Complete Ureteral Obstruction Due to Advanced Prostate Cancer? International Journal of Cancer Management. 2017;10(9).
Quinn DI, Henshall SM, Haynes A-M, Brenner PC, Kooner R, Golovsky D, et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. Journal of Clinical Oncology. 2001;19(16):3692-705.
Katz B, Reis ST, Viana NI, Morais DR, Moura CM, Dip N, et al. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer. PloS one. 2014;9(11):e113700.
Nodouzi V, Nowroozi M, Hashemi M, Javadi G, Mahdian R. Concurrent down-regulation of PTEN and NKX3. 1 expression in Iranian patients with prostate cancer. International braz j urol. 2015;41(5):898-905.
Mishra P, Dauphinee AN, Ward C, Sarkar S, Gunawardena AH, Manjithaya R. Discovery of pan autophagy inhibitors through a high-throughput screen highlights macroautophagy as an evolutionarily conserved process across 3 eukaryotic kingdoms. Autophagy. 2017;13(9):1556-72.
Draz H, Goldberg A, Sanderson T, Safe S. Diindolylmethane and its halogenated analogues induce autophagy in human prostate cancer cells via induction of the astrocyte-elevated gene-1 (AEG-1). AACR; 2017.
Puto LA, Benner C, Hunter T. The DAXX co-repressor is directly recruited to active regulatory elements genome-wide to regulate autophagy programs in a model of human prostate cancer. Oncoscience. 2015;2(4):362.
Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, et al. SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K/mTOR and AR signaling. Cancer cell. 2017;31(3):436-51.
Mani R-S. The emerging role of speckle-type POZ protein (SPOP) in cancer development. Drug discovery today. 2014;19(9):1498-502.
Ju L-G, Zhu Y, Long Q-Y, Li X-J, Lin X, Tang S-B, et al. SPOP suppresses prostate cancer through regulation of CYCLIN E1 stability. Cell Death & Differentiation. 2018:1.
Kwon JE, La M, Oh KH, Oh YM, Kim GR, Seol JH, et al. BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. Journal of Biological Chemistry. 2006.
Puto LA, Brognard J, Hunter T. Transcriptional repressor DAXX promotes prostate cancer tumorigenicity via suppression of autophagy. Journal of Biological Chemistry. 2015:jbc. M115. 658765.
Puto LA, Reed JC. Daxx represses RelB target promoters via DNA methyltransferase recruitment and DNA hypermethylation. Genes & development. 2008;22(8):998-1010.
Tang HW, Wang YB, Wang SL, Wu MH, Lin SY, Chen GC. Atg1‐mediated myosin II activation regulates autophagosome formation during starvation‐induced autophagy. The EMBO journal. 2011;30(4):636-51.
Zalckvar E, Berissi H, Eisenstein M, Kimchi A. Phosphorylation of Beclin 1 by DAP-kinase promotes autophagy by weakening its interactions with Bcl-2 and Bcl-XL. Autophagy. 2009;5(5):720-2.
Anguiano J, Garner TP, Mahalingam M, Das BC, Gavathiotis E, Cuervo AM. Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives. Nature chemical biology. 2013;9(6):374.
Morell C, Bort A, Vara-Ciruelos D, Ramos-Torres Á, Altamirano-Dimas M, Díaz-Laviada I, et al. Up-regulated expression of LAMP2 and autophagy activity during neuroendocrine differentiation of prostate cancer LNCaP cells. PloS one. 2016;11(9):e0162977.
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. The American journal of surgical pathology. 2016;40(2):244-52.
Wang X, Dalkic E, Wu M, Chan C. Gene module level analysis: identification to networks and dynamics. Current opinion in biotechnology. 2008;19(5):482-91.
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature genetics. 2012;44(6):685.
Wang H, Barbieri CE, He J, Gao Y, Shi T, Wu C, et al. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics. Journal of translational medicine. 2017;15(1):175.
Boutros PC. The path to routine use of genomic biomarkers in the cancer clinic. Genome research. 2015;25(10):1508-13.
Tsourlakis MC, Schoop M, Plass C, Huland H, Graefen M, Steuber T, et al. Overexpression of the chromatin remodeler death-domain–associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence. Human pathology. 2013;44(9):1789-96.
Rivera-Gonzalez GC, Droop AP, Rippon HJ, Tiemann K, Pellacani D, Georgopoulos LJ, et al. Retinoic acid and androgen receptors combine to achieve tissue specific control of human prostatic transglutaminase expression: a novel regulatory network with broader significance. Nucleic acids research. 2012;40(11):4825-40.
Chen H-L, Seol H, Brown KJ, Gordish-Dressman H, Hill A, Gallo V, et al. Secretome survey of human plexiform neurofibroma derived Schwann cells reveals a secreted form of the RARRES1 protein. International journal of molecular sciences. 2012;13(7):9380-99.
Coyle KM, Murphy JP, Vidovic D, Vaghar-Kashani A, Dean CA, Sultan M, et al. Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1. Oncotarget. 2016;7(28):44096.
Kwok WK, Pang JCS, Lo KW, Ng H-K. Role of the RARRES1 gene in nasopharyngeal carcinoma. Cancer genetics and cytogenetics. 2009;194(1):58-64.
Wu C-C, Shyu R-Y, Chou J-M, Jao S-W, Chao P-C, Kang J-C, et al. RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma. European Journal of Cancer. 2006;42(4):557-65.
Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nature reviews Clinical oncology. 2011;8(9):528.
Appelqvist H, Wäster P, Kågedal K, Öllinger K. The lysosome: from waste bag to potential therapeutic target. Journal of molecular cell biology. 2013;5(4):214-26.
Fehrenbacher N, Bastholm L, Kirkegaard-Sørensen T, Rafn B, Bøttzauw T, Nielsen C, et al. Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer research. 2008;68(16):6623-33.